Magnesium sulfate therapy of preeclampsia: An old tool with new mechanism of action and prospect in management and prophylaxis

Hypertension Research

Volumn 35, Issue 10, 2012, Pages 1005-1011

  Korish, Aida A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

angiogenic antiangiogenic growth factors; endoglin; magnesium sulfate therapy; preeclampsia; soluble fm like tyrosine kinase 1

Indexed keywords

CD135 ANTIGEN; ENDOGLIN; MAGNESIUM SULFATE; NITRIC OXIDE; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ARTICLE; BIOAVAILABILITY; BODY WEIGHT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; FETOPLACENTAL UNIT; HISTOPATHOLOGY; HYPERTENSION; KIDNEY PARENCHYMA; NEWBORN; NONHUMAN; PLACENTA CIRCULATION; PREECLAMPSIA; PROPHYLAXIS; PROTEINURIA; RAT; SYSTOLIC BLOOD PRESSURE;

ANIMALS; FEMALE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAGNESIUM; MAGNESIUM SULFATE; NITRIC OXIDE; PRE-ECLAMPSIA; PREGNANCY; PROTEINURIA; RATS; RATS, WISTAR; SYSTOLE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84867228688     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2012.103     Document Type: Article

References (45)

1. Roberts JM, Pearson G, Cutler J, Lindheimer M. Summary of the NHLBI Working Group on Research in Hypertension During Pregnancy. Hypertension 2003; 41: 437-445.
2. WHO. Global Burden of Disease for the Year 2001 by World Bank Region, for Use in Disease Control Priorities in Developing Countries. National Institutes of Health, Bethesda, MD, 2004.
3. WHO. Make Every Mother and Child Count. In: World Health Report. World Health Organization, Geneva, 2005.
4. Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, Bujold E, Gonçalves L, Gomez R, Edwin S, Mazor M. Plasma soluble vascular endothelial growth factor receptor-1 concentrations elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17: 3-18.
5. Silasi M, Cohen B, Karumanchi SA, Rana S. Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia. Obstet Gynecol Clin North Am 2010; 37: 239-253.
6. Steinberg G, Khankin EV, Karumanchi SA. Angiogenic factors and preeclampsia. Thromb Res 2009; 123: S93-S99.
7. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683.
8. Clark's DE, Smith SK, He Y, Day KA. Vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998; 59: 1540-1548.
9. Lyall F, Greer IA, Boswell F, Fleming R. Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in preeclampsia. Br J Obstetrics Gynecol 1997; 104: 223-228.
10. Traquilli AL, Bezzeccheri V, Giannubilo SR. Amniotic vascular endothelial growth factor (VEGF) and nitric oxide (NO) in women with subsequent preeclampsia. Eur J Obstet Gynecol Reprod Biol 2004; 113: 17-20.
11. Matsubara K, Matsubara Y, Hyodo S, Katayama T, Ito M. Role of nitric oxide and reactive oxygen species in the pathogenesis of preeclampsia. J Obstet Gynaecol Res 2010; 36: 239-247.
12. El Salahy EM, Ahmed MI, EL-Gharieb A, Tawfik H. New scope in angiogenesis: role of vascular endothelial growth factor (VEGF), NO, lipid peroxidation, and vitamin E in the pathophysiology of pre-eclampsia among Egyptian females. Clin Biochem 2001; 34: 323-329.
13. Duley L, Henderson-Smart D. Magnesium sulfate versus phenytoin for eclampsia. Cochrane Database Syst Rev 2003, CD000128.
14. de Moura RS, Resende AC, Moura AS, Maradei MF. Protective action of a hydroalcoholic extract of a vinifera grape skin on experimental preeclampsia in rats. Hypertens Pregnancy 2007; 26: 89-100.
15. Coates BJ, Broderick TL, Batia LM, Standley CA. MgSO4 prevents left ventricular dysfunction in an animal model of preeclampsia. Am J Obstet Gynecol 2006; 195: 1398-1403.
16. Green LC, Wanger DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate&nitrite and (15N) nitrate in biological fluids. Anal Biochem 1982; 126: 131-138.
17. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658.
18. Vuorela P. Amniotic fluid-soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obestet Gynecol 2000; 95: 353-357.
19. Luft F. Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule. Nephrol Dial Transplant 2006; 21: 3052-3054.
20. Helske S, Vuorela P, Carpen O, Horing C, Weich H, Halmeshmaki E. Expression of vascular endothelial growth factors 1, 2, and3 in placentas from normal and complicated pregnancies. Mol Hum Reprod 2011; 7: 205-210.
21. Thadhani R, Mutter W, Wolf M, Levine R, Taylor R, Sukhatme V, Ecker J, Karumanchi S. First trimester placental growth factor and soluble Fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89: 770-775.
22. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-tovi S, Gomez R, Edwin S, Chaiworapongsa T, Levine RJ, Karumanchi A. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble VEGF receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small-for-gestational-age neonate. J Matern Fetal Neonatal Med 2008; 21: 9-23.
23. Reuvekamp A, Velsing-Aarts FV, Poulina IE, Capello JJ, Duits AJ. Selective deficit of angiogenic growth factors characterizes pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol 1999; 106: 1019-1022.
24. Hornig C, Barleon B, Ahmad S, Vuorela P, Ahmed A, Weich HA. Release and complex formation of soluble VEGFR1 from endothelial cells and biological fluids. Lab Invest 2000; 80: 443-454.
25. Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003; 1: 1356-1370.
26. Kim YN, Lee DS, Jeong DH, Sung MS, Kim KT. The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Prenat Diagn 2009; 29: 464-470.
27. Aggarwal PK, Chandel N, Jain V, Jha V. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. J Hum Hypertens 2012; 26: 236-241.
28. Zhao F. Ca, Mg, Cu and Zn contents of the maternal and umbilical cord serum in pregnancy-induced hypertension. Zhonghua Fu Chan Ke Za Zhi 1989; 24: 212-214.
29. Sanders R, Konijnenberg A, Huijgen HJ, Wolf H, Boer K, Sanders GT. Intracellular and extracellular, ionized and total magnesium in pre-eclampsia and uncomplicated pregnancy. Clin Chem Lab Med 1999; 37: 55-59.
30. Sukonpan K, Phupong V. Serum calcium and serum magnesium in normal and preeclamptic pregnancy. Arch Gynecol Obstet 2005; 273: 12-16.
31. Standley CA, Whitty JE, Mason BA, Cotton DB. Serum ionized magnesium levels in normal and preeclamptic gestation. Obstet Gynecol 1997; 89: 24-27.
32. Kemp PA, Gardinerm SM, March JE, Rubin PC, Bennett T. Assessment of the effects of endothelin-1 and magnesium sulfate on regional blood flows in conscious rats, by the coloured microsphere reference technique. Br J Pharmacol 1999; 126: 621-626.
33. Woods KL, Fletcher F, Roffe C, Haider Y. Intravenous magnesium sulfate in suspected acute myocardial infarction: results of the second leicester intravenous magnesium intervention trial (LIMIT-2). Lancet 1992; 339: 1553-1558.
34. Omu AE, Al-Harmi J, Vedi HL, Mlechkova L, Sayed AF, Al-Ragum NS. Magnesium sulfate therapy in women with pre-eclampsia and eclampsia in Kuwait. Med Princ Pract 2008; 17: 227-232.
35. Xu B, Thornton C, Tooher J, Ogle R, Lim S, Makris A, Hennessy A. Effects of antihypertensive drugs on production of soluble fms-like tyrosine kinase 1 and soluble endoglin from human normal and pre-eclamptic placentas in vitro. Clin Exp Pharmacol Physiol 2009; 36: 839-842.
36. Connolly DT, Heuvelman DM, Nelson R, Olander JV. Tumour vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989; 84: 1470-1478.
37. Morbidelli L, Chang CH, Douglas JG, Granger HJ, Ledda F, Ziche M. Nitric oxide mediates mitogenic effect of VEGF on coronary vascular endothelium. Am J Physiol 1996; 270: H411-H415.
38. He H, Venema VJ, X GU, Venema RC, Marrero MB, Caldwell RB. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem 1999; 274: 25130-25135.
39. Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007; 197: 244.e1-244.e8.
40. Shaamash AH, Elsonosy ED, Zakhari MM, Radwan SH, El-Deien HM. Placental nitric oxide synthase (NOS) activity and nitric oxide (NO) production in normal pregnancy, pre-eclampsia and eclampsia. Int J Gynecol Obstet 2001; 72: 127-133.
41. Ostendorf T. VEGF (165) mediates glomerular endothelial repair. J Clin Biol Chem 1999; 104: 913-923.
42. Nobunaga T, Tokugawa Y, Hashimoto K. Plasma nitric oxide levels in pregnant patients with preeclampsia and essential hypertension. Gynecol Obest Invest 1996; 41: 189-193.
43. Kovac CM, Howard BC, Pierce BT, Hoeldtke NJ, Calhoun BC, Napolitano PG. Fetoplacental vascular tone is modified by magnesium sulfate in the preeclamptic ex vivo human placental cotyledon. Am J Obstet Gynecol 2003; 189: 839-842.
44. Gao H, Zou L. Effect of magnesium sulfate on fetal rats of fetal growth retardation and its relation with expression of caspase-3 on the placenta of maternal rat. Zhonghua Fu Chan Ke Za Zhi 2006; 41: 525-528.
45. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R. High affinity VEGF binding and developmental expression suggest FLK-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 72: 835-846.